5D8.F · Deinove SA
-
-
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| ISIN | FR0010879056 |
| CurrencyCode | EUR |
| Exchange | F |
| Market Cap | 847K |
|---|---|
| Beta | 0.79 |
| Dividend Yield | 0.0% |
| Target Price | None |
| PE Ratio | None |
ABOUT
Deinove SA
DEINOVE SA, a biotechnology company, discovers, develops, and produces compounds from microbials for the health, nutrition, and cosmetics industries worldwide. The company's pipeline includes DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers Dual-Acting Small Molecule Antibiotics, a class of dual activity antibiotics that develops a new class of 2-in-1 molecules whose structure results from the combination of two active antibiotic moieties. The company was founded in 2006 and is based in Grabels, France.
Learn More